Correlation between serum ficolin and coronary artery stenosis and its influence on prognosis in patients with coronary heart disease

doi:10.11958/20221707

Abstract

Abstract:

Objective To investigate the correlation between Ficolin-2, Ficolin-3 and the degree of coronary artery stenosis in patients with coronary heart disease and its influence on prognosis. Methods A total of 137 patients with stable coronary heart disease were classified as the coronary heart disease group. Gensini score was used to evaluate the degree of coronary artery stenosis. According to the score, patients were divided into the mild group (56 cases), the moderate group (49 cases) and the severe group (32 cases). According to the occurrence of major adverse cardiac events (MACEs) within 3 months, patients were divided into the good prognosis group (108 cases) and the poor prognosis group (29 cases). Sixty healthy subjects in the same period were selected as the control group. The clinical data of each group were collected, and serum levels of Ficolin-2 and Ficolin-3 were detected. Pearson product moment correlation analysis was used to analyze the correlation between Ficolin-2, Ficolin-3 and Gensini. Logistic regression analysis was used to analyze the influencing factors of poor prognosis. The working characteristic (ROC) curve of subjects was used to evaluate the predictive value of Ficolin-2 and Ficolin-3 for the poor prognosis. Results The serum levels of Ficolin-2 and Ficolin-3 were lower in the coronary heart disease group than those in the control group (P<0.05). The serum levels of Ficolin-2 and Ficolin-3 in the mild group, the moderate group and the severe group were decreased successively (P<0.05). The serum Ficolin-2 and Ficolin-3 levels were negatively correlated with the Gensini score in patients with coronary heart disease (r=-0.708, -0.722, P<0.05). The number of coronary artery lesions and Gensini score were independent risk factors for poor prognosis in patients with coronary heart disease [OR=1.451 (95%CI: 1.292-1.628)]. The higher levels of Ficolin-2 and Ficolin-3 were independent protective factors [OR=0.815 (95%CI: 0.730-0.909) and 0.853 (95%CI: 0.787-0.924)]. The AUC of the combination of Ficolin-2 and Ficolin-3 in predicting the poor prognosis of patients with coronary heart disease was higher than that of the single index (Z=3.186, 2.953, P<0.05). Conclusion The serum levels of Ficolin-2 and Ficolin-3 are decreased in patients with coronary heart disease, and are negatively correlated with the degree of coronary artery stenosis. The combined detection of the two indicators can predict the poor prognosis of patients with coronary heart disease, and the sensitivity is high.

Key words: coronary disease, coronary stenosis, sensitivity and specificity, fibroglutinin 2, fibroglutinin 3, major adverse cardiac events

CLC Number:

R541.4

Figures/Tables 6

References 22

[1]	NIDORF S M, FIOLET ATL, MOSTERD A, et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med, 2020, 383(19):1838-1847. doi:10.1056/NEJMoa2021372.
[2]	KONG P, CUI Z Y, HUANG X F, et al. Inflammation and atherosclerosis:signaling pathways and therapeutic intervention[J]. Signal Transduct Target Ther, 2022, 7(1):131. doi: 10.1038/s41392-022-00955-7.
[3]	POTHINENI N V K, SUBRAMANY S, KURIAKOSE K, et al. Infections,atherosclerosis,and coronary heart disease[J]. Eur Heart J, 2017, 38(43):3195-3201. doi:10.1093/eurheartj/ehx362.
[4]	DRAPKINA O M, GEGENAVA B B, FOMIN V V. The role of the mLDL-induced activation of the complement system classical pathway and C3 expression stimulation in atherosclerosis[J]. Ter Arkh, 2018, 90(4):100-104. doi:10.26442/terarkh2018904100-104.
[5]	PIECZARKA C, ANDRADE F A, CATARINO S J, et al. Ficolin-1 and ficolin-3 polymorphisms and susceptibility to rheumatoid arthritis[J]. Autoimmunity, 2020, 53(7):400-407. doi:10.1080/08916934.2020.1809654.
[6]	JARLHELT I, PILELY K, CLAUSEN J B, et al. Circulating Ficolin-2 and Ficolin-3 form heterocomplexes[J]. J Immunol, 2020, 204(7):1919-1928. doi:10.4049/jimmunol.1900694.
[7]	LI Y, YOU E Q, LIN W H, et al. Association of ficolin-1 and ficolin-3 gene variation and pulmonary tuberculosis susceptibility in a Chinese population[J]. J Clin Lab Anal, 2021, 35(4):e23732. doi:10.1002/jcla.23732.
[8]	GIRAUDI P J, SALVOZA N, BONAZZA D, et al. Ficolin-2 plasma level assesses liver fibrosis in non-alcoholic fatty liver disease[J]. Int J Mol Sci, 2022, 23(5):2813. doi: 10.3390/ijms23052813.
[9]	LEVINE G N, BATES E R, BLANKENSHIP J C, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction:An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. Circulation, 2016, 133(11):1135-1147. doi: 10.1161/CIR.0000000000000336.
[10]	GENSINI G G. A more meaningful scoring system for determining the severity of coronary heart disease[J]. Am J Cardiol, 1983, 51(3):606. doi:10.1016/s0002-9149(83)80105-2.
[11]	KATTA N, LOETHEN T, LAVIE C J, et al. Obesity and coronary heart disease: epidemiology,pathology,and coronary artery imaging[J]. Curr Probl Cardiol, 2021, 46(3):100655. doi:10.1016/j.cpcardiol.2020.100655.
[12]	MUSCELLA A, STEFÀNO E, MARSIGLIANTE S. The effects of exercise training on lipid metabolism and coronary heart disease[J]. Am J Physiol Heart Circ Physiol, 2020, 319(1):H76-H88. doi: 10.1152/ajpheart.00708.2019.
[13]	陈建华, 刘艳影. 冠心病患者CRP、PCT、SAA水平与冠状动脉粥样硬化程度的相关性分析[J]. 现代诊断与治疗, 2022, 33(2):271-273,290.
	CHEN J H, LIU Y Y. Correlation between the levels of CRP,PCT,SAA and degree of coronary atherosclerosis in patients with coronary heart disease[J]. Modern Diagnosis and Treatment, 2022, 33(2):271-273,290.
[14]	刘艾婷, 彭旷, 欧蕾宇, 等. 补体系统在动脉粥样硬化中的作用研究进展[J]. 中国动脉硬化杂志, 2021, 29(4):363-368.
	LIU A T, PENG K, OU L Y, et al. A review about the role of complement system in atherosclerosis[J]. Chinese Journal of Arteriosclerosis, 2021, 29(4):363-368. doi:10.3969/j.issn.1007-3949.2021.04.017.
[15]	吴嘉, 汪俊军. 补体系统在动脉粥样硬化性心血管疾病中的研究与应用[J]. 中华检验医学杂志, 2020, 43(9):855-859.
	WU J, WANG J J. Research and application of complement system in atherosclerotic cardiovascular disease[J]. Chinese Journal of Laboratory Medicine, 2020, 43(9):855-859. doi:10.3760/cma.j.cn114452-20200521-00488.
[16]	SCRIBA T J, PENN-NICHOLSON A, SHANKAR S, et al. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease[J]. PLoS Pathog, 2017, 13(11):e1006687. doi:10.1371/journal.ppat.1006687.
[17]	MO X G, LIU W, YANG Y, et al. NCF2,MYO1F,S1PR4,and FCN1 as potential noninvasive diagnostic biomarkers in patients with obstructive coronary artery:A weighted gene co-expression network analysis[J]. J Cell Biochem, 2019, 120(10):18219-18235. doi: 10.1002/jcb.29128.
[18]	OHASHI T, ERICKSON H P. The disulfide bonding pattern in ficolin multimers[J]. J Biol Chem, 2004, 279(8):6534-6539. doi:10.1074/jbc.M310555200.
[19]	BABAHA F, ABOLHASSANI H, HAMIDI ESFAHANI Z, et al. A new case of congenital ficolin-3 deficiency with primary immunodeficiency[J]. Expert Rev Clin Immunol, 2020, 16(7):733-738. doi: 10.1080/1744666X.2020.1792779.
[20]	贾耀辉, 陈慧敏, 代永庆, 等. 血清硫氧还蛋白1及纤维胶凝蛋白3水平与老年高血压脑出血患者血肿周围水肿和预后的关系研究[J]. 中国实用神经疾病杂志, 2021, 24(21):1889-1899.
	JIA Y H, CHEN H M, DAI Y Q, et al. Relationship between serum levels of Trx1,ficolin-3 and perihematoma edema and prognosis in elderly patients with hypertensive intracerebral hemorrhage[J]. Chinese Journal of Practical Nervous Diseases, 2021, 24(21):1889-1899. doi:10.12083/SYSJ.2021.21.001.
[21]	TROLDBORG A, STEFFENSEN R, TRENDELENBURG M, et al. Ficolin-3 deficiency is associated with disease and an increased risk of systemic lupus erythematosus[J]. J Clin Immunol, 2019, 39(4):421-429. doi:10.1007/s10875-019-00627-2.
[22]	CARBONE F, VALENTE A, PEREGO C, et al. Ficolin-2 serum levels predict the occurrence of acute coronary syndrome in patients with severe carotid artery stenosis[J]. Pharmacol Res, 2021, 166:105462. doi:10.1016/j.phrs.2021.105462.

组别	n	Ficolin-2	Ficolin-3
对照组	60	15.39±3.17	22.64±4.83
冠心病组	137	8.76±2.52	13.09±4.11
t		9.062^＊＊	14.219^＊＊

组别	n	Ficolin-2	Ficolin-3
对照组	60	15.39±3.17	22.64±4.83
冠心病组	137	8.76±2.52	13.09±4.11
t		9.062^＊＊	14.219^＊＊

组别	n	Ficolin-2	Ficolin-3
轻度组	56	10.25±1.98	15.61±2.78
中度组	49	8.37±2.05^a	12.59±2.34^a
重度组	32	6.80±1.53^ab	10.46±2.80^ab
F		34.832^＊＊	41.853^＊＊

组别	n	Ficolin-2	Ficolin-3
轻度组	56	10.25±1.98	15.61±2.78
中度组	49	8.37±2.05^a	12.59±2.34^a
重度组	32	6.80±1.53^ab	10.46±2.80^ab
F		34.832^＊＊	41.853^＊＊

组别	n	性别（男/女）	年龄/岁	BMI/（kg/m²）	冠心病病程/年	吸烟史	饮酒史	心血管病家族史	糖尿病史	冠状动脉单支病变
预后良好组	108	57/51	63.97±9.05	22.13±1.87	6.35±1.76	35（32.4）	46（42.6）	17（15.7）	20（18.5）	59（54.6）
预后不良组	29	18/11	62.85±8.76	22.80±1.51	6.95±1.62	10（34.5）	15（51.7）	6（20.7）	9（31.0）	3（10.3）
t或χ²		0.797	0.609	1.783	1.667	0.045	0.772	0.401	2.146	18.103^＊＊
组别	FBG/（mmol/L）	TC/（mmol/L）	TG/（mmol/L）	HDL-C/（mmol/L）	LDL-C/（mmol/L）	Ficolin-2/（mg/L）	Ficolin-3/（mg/L）
预后良好组	6.08±0.73	3.29±0.58	1.34±0.28	1.75±0.51	2.76±0.63	9.64±2.01	14.22±2.46
预后不良组	6.13±0.67	3.34±0.60	1.31±0.32	1.82±0.49	2.79±0.68	6.58±2.23	10.37±2.25
t	0.332	0.419	0.508	0.662	0.227	7.115^＊＊	7.614^＊＊